Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy

References

• Epstein RS, Aapro MS, Basu Roy UK, et al. Patient burden and real-world management of chemotherapy-induced myelosuppression: results from an online survey of patients with solid tumors. Adv Ther. 2020;37(8):3606–3618.
   PubMed Web of Science ®Google Scholar
• Bagnyukova TV, Serebriiskii IG, Zhou Y, et al. Chemotherapy and signaling: how can targeted therapies supercharge cytotoxic agents? Cancer Biol Ther. 2010;10(9):839–853.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology. 2015;29(4):282–294.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229.
   PubMed Web of Science ®Google Scholar
• Liou SY, Stephens JM, Carpiuc KT, et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig. 2007;27(6):381–396.
   PubMed Web of Science ®Google Scholar
• Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. Int J Clin Transf Med. 2018;6:21–31.
   Google Scholar
• Tai E, Guy GP, Dunbar A, et al. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552–e561.
   PubMed Web of Science ®Google Scholar
• Baugh CW, Faridi MK, Mueller EL, et al. Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia. PLoS One. 2019;14(5):e0216835.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics [Internet]. Consumer price index. Washington (DC): U.S. Bureau of Labor Statistics; 2020 [cited 2020 April 21]. Available from: https://www.bls.gov/cpi/tables/
   Google Scholar
• Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS One. 2018;13(4):e0196007.
   PubMed Web of Science ®Google Scholar
• Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020;136(7):801–813.
   PubMed Web of Science ®Google Scholar
• NCCN [Internet]. Clinical Practice Guidelines in Oncology. Hematopoietic Growth Factors, version 4.2021 [cited 2021 November 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf
   Google Scholar
• He S, Roberts PJ, Sorrentino JA, et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med. 2017;9(387):eaal3986.
   PubMed Web of Science ®Google Scholar
• Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019;30(10):1613–1621.
   PubMed Web of Science ®Google Scholar
• Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. Int J Cancer. 2021;148(10):2557–2570.
   PubMed Web of Science ®Google Scholar
• Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350–365.
   PubMed Web of Science ®Google Scholar
• G1 Therapeutics [Internet]. COSELA™ (trilaciclib). Full prescribing information. Research Triangle Park (NC): G1 Therapeutics; 2021 [cited 2021 March 3]. Available from: https://www.g1therapeutics.com/cosela/pi/
   Google Scholar
• NCCN [Internet]. Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer, version 3.2021 [cited 2021 November 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
   Google Scholar
• Weiss J, Goldschmidt J, Andric Z, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer. 2021;22(5):449–460.
   PubMed Web of Science ®Google Scholar
• Drugs.com [Internet]. Drug price information from Drugs.com; c2000-2021. 2019 [cited 2019 December 31]. Available from: https://www.drugs.com/price-guide/
   Google Scholar
• Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008;11(2):172–179.
   PubMed Web of Science ®Google Scholar
• Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013;13:11.
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Edelsberg J, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract. 2015;11(1):47–54.
   PubMed Web of Science ®Google Scholar
• International Business Machines [Internet]. IBM Watson Health Micromedex® Red Book; 2021 [cited 2019 December 31]. Available from: https://www.ibm.com/uk-en/products/micromedex-red-book
   Google Scholar
• Teckle P, McTaggart-Cowan H, Van der Hoek K, et al. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. Health Qual Life Outcomes. 2013;11:203.
   PubMed Web of Science ®Google Scholar
• Duh MS, Hackshaw MD, Ivanova JI, et al. Costs associated with intravenous cancer therapy administration in patients with metastatic soft tissue sarcoma in a US population. Sarcoma. 2013;2013:947413.
   PubMedGoogle Scholar
• Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the functional assessment of cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern cooperative oncology group (ECOG) study 5592. J Clin Epidemiol. 2002;55(3):285–295.
   PubMed Web of Science ®Google Scholar
• Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24(6):547–561.
   PubMed Web of Science ®Google Scholar
• Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005;28(2):172–191.
   PubMed Web of Science ®Google Scholar
• Butt Z, Webster K, Eisenstein AR, et al. Quality of life in lung cancer: the validity and cross-cultural applicability of the functional assessment of cancer Therapy-Lung Scale. Hematol Oncol Clin North Am. 2005;19(2):389–420.
   PubMed Web of Science ®Google Scholar
• Vreman RA, Geenen JW, Knies S, et al. The application and implications of novel deterministic sensitivity analysis methods. Pharmacoeconomics. 2021;39(1):1–17.
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. In: Handbooks in health economic evaluation. Vol. 1. Oxford (UK): Oxford University Press; 2006.
   Google Scholar
• Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. 5th ed. Boston (MA): Houghton Mifflin; 2002.
   Google Scholar
• Institute for Clinical and Economic Review [Internet]. 2020-2023 value assessment framework. Boston (MA): ICER; 2020 [cited 2020 January 31]. Available from: https://34eyj51jerf417itp82ufdoe-wpengine.netdna-ssl.com/wp-content/uploads/2021/03/ICER_2020_2023_VAF_013120-4-2.pdf
   Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–924.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Del Mastro L, Bellodi A, et al. The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol. 2014;89(1):112–128.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the research on adverse drug events and reports (RADAR) project. Br J Haematol. 2006;135(5):642–650.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist. 2007;12(4):478–483.
   PubMed Web of Science ®Google Scholar
• Calhoun EA, Schumock GT, McKoy JM, et al. Granulocyte colony–stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited. Pharmacoeconomics. 2005;23(8):767–775.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lalla A, Barron RL, et al. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther. 2009;31(5):1092–1104.
   PubMed Web of Science ®Google Scholar
• Fust K, Li X, Maschio M, et al. Cost-Effectiveness analysis of prophylaxis treatment strategies to reduce the incidence of febrile neutropenia in patients with Early-Stage breast cancer or Non-Hodgkin lymphoma. Pharmacoeconomics. 2017;35(4):425–438.
   PubMed Web of Science ®Google Scholar
• Liu Z, Doan QV, Malin J, et al. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy. 2009;7(3):193–205.
   PubMedGoogle Scholar
• Hill G, Barron R, Fust K, et al. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses. J Med Econ. 2014;17(1):32–42.
   PubMedGoogle Scholar
• Lee EK, Wong WW, Trudeau ME, et al. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Res Treat. 2015;150(1):169–180.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health. 2009;12(2):217–225.
   PubMed Web of Science ®Google Scholar
• Aarts MJ, Grutters JP, Peters FP, et al. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol. 2013;31(34):4283–4289.
   PubMed Web of Science ®Google Scholar
• Whyte S, Cooper KL, Stevenson MD, et al. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Value Health. 2011;14(4):465–474.
   PubMed Web of Science ®Google Scholar
• Bojke L, Sculpher M, Stephens R, et al. Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the medical research council LU19 trial. Pharmacoeconomics. 2006;24(5):443–452.
   PubMed Web of Science ®Google Scholar
• Li YYR, Mai H, Trudeau ME, et al. Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada. Curr Oncol. 2020;27(5):e495–e500.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Lane D, Stinson T, et al. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest. 2001;19(2):107–113.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making. 2012;32(5):722–732.
   PubMed Web of Science ®Google Scholar
• Hatswell AJ, Bullement A, Briggs A, et al. Probabilistic sensitivity analysis in Cost-Effectiveness models: determining model convergence in cohort models. Pharmacoeconomics. 2018;36(12):1421–1426.
   PubMed Web of Science ®Google Scholar